Collaborative diabetes tech on the Horizon
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Olympus banks on acquisitions to sustain its high
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Philips sells the household goods and could spend on tech instead
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Abbott and J&J start the year from different places
Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
Poor fourth quarter mars strong year for medtech floats
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
Bioresorbable scaffolds flounder as Reva heads to bankruptcy
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
A quiet six months for device approvals
The second half of 2019 saw half as many innovative medical devices approved as the first.
A thoroughly average year for medtech mergers
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
How low can medtech venture investment go?
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
